# Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

> **NCT00765973** · PHASE1 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 14 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Ovarian Cancer
- Solid Tumors

## Interventions

- **DRUG:** Topotecan Liposomes Injection (TLI)
- **DRUG:** Topotecan Liposomes Injection (TLI)

## Key facts

- **NCT ID:** NCT00765973
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-10
- **Primary completion:** 2010-06-30
- **Final completion:** 2010-06-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765973, "Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00765973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*